Clinical Trials Logo

Filter by:
NCT ID: NCT02267486 Completed - Alzheimer Dementia Clinical Trials

Exploratory Study for the Validity of QuQu Scale

QuQu
Start date: October 2014
Phase: N/A
Study type: Observational

Examine the construct validity, the group discriminant ability, and the inter-rater reliability of a novel dementia rating scale (QuQu scale: QUick QUestion scale) candidate for the evaluation of patients with Alzheimer Dementia (AD)

NCT ID: NCT02267343 Completed - Gastric Cancer Clinical Trials

Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

Start date: October 2014
Phase: Phase 3
Study type: Interventional

The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.

NCT ID: NCT02265939 Completed - Bowel Disease Clinical Trials

Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy

Start date: October 2014
Phase: Phase 2
Study type: Interventional

Patients who require screening colonoscopy will receive an intraluminal spraying of NPO-13 per contraction region of large bowel up to fifth times during the colonoscopy. The efficacy of NPO-13 will be evaluated based on the proportion of the splayed region with no contraction after NPO-13 dosage (primary outcome measure). The colonic spasm will be assessed by an independent committee using recorded video images. The safety of NPO-13 will be evaluated based on adverse events and adverse drug reactions (ADRs) observed between administration and seven days after administration.

NCT ID: NCT02265744 Completed - Lupus Clinical Trials

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Start date: November 13, 2014
Phase: Phase 2
Study type: Interventional

Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic lupus erythematosus in male and female adults. Patients who qualify will be randomized to either active BMS-931699 or placebo for initially, up to 24 weeks. Patients who complete the initial 24 weeks of treatment and who are responding to therapy will have the option to continue receiving BMS-931699 as part of a long-term extension (LTE). Disease activity and safety will be assessed over the course of the study through laboratory values, various rating scales accepted in systemic lupus erythematosus studies and patient self reporting.

NCT ID: NCT02265731 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Start date: September 22, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.

NCT ID: NCT02264990 Completed - Clinical trials for Non-squamous Non-small Cell Lung Cancer

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Start date: September 30, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.

NCT ID: NCT02263911 Completed - Healthy Volunteers Clinical Trials

A Study of Baricitinib in Healthy Japanese Participants

Start date: November 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to understand the relationship of 3 different dosage forms of baricitinib. This study will also explore the effect of food on how the body absorbs baricitinib. This study will last about 5 weeks, not including screening. Screening is required within 28 days prior to the date of first dosing.

NCT ID: NCT02261974 Completed - Clinical trials for Vaginal Laxity Following Childbirth

VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness

VIVEVE I
Start date: January 2015
Phase: N/A
Study type: Interventional

Outside United States (OUS) Post-Market Parallel Group Exploratory Study Design The objective of this study is to determine the safety and effectiveness of the Viveve System to treat the vaginal introitus in women following vaginal birth(s) and in so doing improving vaginal laxity.

NCT ID: NCT02260986 Completed - Atopic Dermatitis Clinical Trials

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

CHRONOS
Start date: September 2014
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.

NCT ID: NCT02260687 Completed - Clinical trials for Choroidal Neovascularization

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Start date: December 5, 2014
Phase:
Study type: Observational

The objectives of this study are to investigate the safety and effectiveness of EYLEA.